|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Iressa film-coated tab[艾瑞莎 膜衣錠] information |
|
|
|
製造商 |
AstraZeneca |
|
代理/經銷商 |
AstraZeneca |
|
成份 |
Gefitinib |
|
適應症 |
1st-line treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have activating mutations of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK). Treatment of patients with locally advanced or metastatic adenocarcinoma of the lung who have previously received chemotherapy. |
|
用量 |
250 mg once daily. |
|
過量 |
View Iressa[艾瑞莎] overdosage for action to be taken in the event of an overdose. |
|
用法 |
May be taken with or without food (May also be dispersed in ½ glass of plain, non-carbonated water. No other liqds should be used. Drop the tab in water & stir w/out crushing until it disperses (approx 10 mins). Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via NG tube.). |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Severe hypersensitivity. |
|
注意事項 |
Monitor for interstitial lung disease in patients with concurrent idiopathic pulmonary fibrosis/interstitial pneumonia/pneumoconiosis/radiation pneumonia/drug-induced pneumonia. If patients present with worsening of respiratory symptoms eg, dyspnea, cough & fever, interrupt treatment & initiate prompt investigation. If interstitial lung disease is confirmed, Iressa should be discontinued & the patient treated appropriately. Periodic liver function testing is recommended, use with caution in the presence of mild to moderate increases of liver transaminases. Co-administration with CYP3A4 inducers or drugs that cause significant sustained elevations in gastric pH may reduce drug efficacy. Patients taking warfarin should have their prothrombin time or INR monitored. Patients are advised to report promptly any eye symptoms or severe or persistent diarrhea, nausea, vomiting or anorexia. Avoid in pregnancy, lactation. Caution in driving or operating machinery. |
|
不良反應 |
GI disturbances: diarrhea, nausea, vomiting, stomatitis, dehydration, dry mouth. Liver function abnormalities. Anorexia. Skin reactions. Asthenia. Hemorrhage eg epistaxis & hematuria. Asymptomatic laboratory elevations in blood creatinine, proteinuria. Nail disorder, alopecia. Pyrexia. Conjunctivitis, blepharitis & dry eye. Severe interstitial lung disease have been reported.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Co-administration with rifampicin & ranitidine reduced mean gefitinib AUC. Co-administration with itraconazole increase the mean AUC of gefitinib. INR elevations &/or bleeding events have been reported in patients taking warfarin.
View more drug interactions with Iressa[艾瑞莎] |
|
儲存 |
View Iressa[艾瑞莎] storage conditions for details to ensure optimal shelf-life. |
|
作用 |
View Iressa[艾瑞莎] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Iressa 膜衣錠 |
|
Iressa 250 mg x 30's |
 |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
AstraZeneca |
|
|
|
|
|
